Printed from Voxsanity (voxsanity.com.au) — NCT07191821 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Alzheimers Disease
Phase 2 Alzheimer's Disease Trial, By Invitation
NCT07191821
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults between 60 and 90 years old
- Men, or women who have gone through menopause
- Men who are able to father children may be eligible if they are willing to use the contraception methods described in the participant information sheet, during treatment and for 90 days after the last dose
- People who are able to give written consent before any study procedures begin
- People who have a specific genetic variation called the AA genotype at the rs6971 (TSPO) location in their DNA
- People who have been diagnosed with Alzheimer's disease by a dementia specialist, using recognised medical diagnostic guidelines
- People with mild to moderate memory and thinking difficulties, based on a standard cognitive test score between 20 and 27
- People with mild cognitive impairment who have had Alzheimer's disease confirmed through biological markers (such as brain scans or fluid tests)
- Adults aged 18 years or older
- Men or women of any reproductive status
- Women who could potentially become pregnant must be willing to have a pregnancy test before any scanning procedures
- People who are able to give written consent before any study procedures begin
- People who are willing to have blood samples taken for genetic testing (including ApoE and TSPO rs6971 genes)
- People who have had Alzheimer's disease confirmed through biological markers (such as brain scans or fluid tests)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a history of migraines that occur more than once a month
- People with a clinical history suggesting dementia with Lewy bodies, such as a condition called REM Sleep Behaviour Disorder
- People with health conditions that would make it unsafe for them to take part in the study intervention
- People with conditions that would prevent them from completing study procedures, for example severe vision or hearing loss
- People with significant kidney disease (confirm with trial site for specific test values)
- People with significant liver disease shown by abnormal liver function blood test results
- People who cannot have MRI scans or who cannot receive a particular type of contrast dye used in MRI imaging
- People whose Alzheimer's medications (such as galantamine, rivastigmine, or donepezil) or blood pressure medications have been changed in the last 28 days, or where a change is planned during the study
- People with severe breathing disease involving persistently low oxygen levels, known build-up of carbon dioxide in the blood, or a need for home oxygen therapy
- People currently taking certain medications that strongly or moderately affect how the body processes drugs through a liver enzyme called CYP3A4, including a specific list of inhibitors (such as clarithromycin, ketoconazole, itraconazole, voriconazole, erythromycin, fluconazole, diltiazem, verapamil, and others — confirm full list with trial site)
- People currently taking certain medications that strongly or moderately activate the same liver enzyme, including drugs such as carbamazepine, phenytoin, rifampicin, St John's wort, efavirenz, and others — confirm full list with trial site)
- People currently taking oral contraceptives
- People who cannot have MRI scans or who cannot receive the contrast dye used in MRI imaging (this criterion applies specifically to healthy volunteers)
- Women of childbearing potential who are pregnant (this criterion applies specifically to healthy volunteers)
- People with reduced kidney function below a specific threshold (this criterion applies specifically to healthy volunteers — confirm with trial site)
- People with severe breathing disease involving persistently low oxygen levels, known build-up of carbon dioxide, or a need for home oxygen therapy (this criterion applies specifically to healthy volunteers)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
By Invitation
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
8 August 2025
Est. completion
1 March 2027
Where this trial is recruiting
🇬🇧 United Kingdom
Primary endpoints
Does pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days) improve neurovascular coupling (NVC) in people with AD compared to placebo?
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.